RFG Bristol Wealth Advisors LLC Buys New Shares in Eli Lilly and Company (NYSE:LLY)

RFG Bristol Wealth Advisors LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,683 shares of the company's stock, valued at approximately $2,071,000.

Several other hedge funds have also modified their holdings of LLY. Meeder Advisory Services Inc. grew its position in Eli Lilly and Company by 3.4% during the fourth quarter. Meeder Advisory Services Inc. now owns 16,302 shares of the company's stock valued at $12,585,000 after purchasing an additional 541 shares in the last quarter. Groupama Asset Managment boosted its stake in shares of Eli Lilly and Company by 3.8% during the 4th quarter. Groupama Asset Managment now owns 91,838 shares of the company's stock valued at $71,068,000 after buying an additional 3,373 shares during the period. Trexquant Investment LP grew its holdings in shares of Eli Lilly and Company by 73.4% during the 4th quarter. Trexquant Investment LP now owns 4,421 shares of the company's stock valued at $3,413,000 after acquiring an additional 1,871 shares in the last quarter. May Hill Capital LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth $1,205,000. Finally, Invenio Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 6.5% during the fourth quarter. Invenio Wealth Partners LLC now owns 1,609 shares of the company's stock worth $1,242,000 after acquiring an additional 98 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Citigroup lowered their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research report on Thursday, January 16th. Finally, Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,009.72.

Remove Ads

Eli Lilly and Company Stock Up 1.8 %

Shares of NYSE LLY traded up $14.34 during mid-day trading on Wednesday, hitting $819.57. The company had a trading volume of 2,678,114 shares, compared to its average volume of 3,311,810. The company has a market capitalization of $777.09 billion, a PE ratio of 69.99, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The firm has a 50-day simple moving average of $848.85 and a two-hundred day simple moving average of $834.05. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has approved a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board believes its shares are undervalued.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.